Stock ABERA ABERA BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abera Bioscience AB

Equities

ABERA

SE0015245097

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
4.71 SEK -1.26% Intraday chart for Abera Bioscience AB -1.67% -8.72%
Feb. 09 Abera Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
2023 Abera Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 173.1 61.96 72.31 72.31 -
Enterprise Value (EV) 1 173.1 46.52 74.63 72.31 72.31
P/E ratio -18.4 x - - - -
Yield - - - - -
Capitalization / Revenue - 33.5 x 28.2 x 4.55 x 17.2 x
EV / Revenue - 33.5 x 28.2 x 4.55 x 17.2 x
EV / EBITDA - -3.19 x -3.65 x -16.4 x -3.63 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 10,460 12,908 15,352 15,352 -
Reference price 2 16.55 4.800 4.710 4.710 4.710
Announcement Date 2/23/22 5/17/23 2/9/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 1.85 2.646 15.9 4.2
EBITDA 1 - -19.39 -19.8 -4.4 -19.9
EBIT 1 - -19.39 -16.8 -4.4 -19.9
Operating Margin - -1,048.27% -634.96% -27.67% -473.81%
Earnings before Tax (EBT) - - - - -
Net income -9.165 - - - -
Net margin - - - - -
EPS -0.9000 - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 2/23/22 5/17/23 2/9/24 - -
1SEK in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2.6 2.7 5.5 2.3 5.5
EBITDA - - 0.3 - 0.5
EBIT 1 -2.5 -2.5 0.3 -2.8 0.5
Operating Margin -96.15% -92.59% 5.45% -121.74% 9.09%
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS - - - - -
Dividend per Share - - - - -
Announcement Date 2/9/24 - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - 15.4 - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 2/23/22 5/17/23 2/9/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ABERA BIOSCIENCE AB Stock Abera Bioscience AB
-8.72% 6.58M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ABERA Stock
  4. Financials Abera Bioscience AB